Look to BioFluidica LiquidScan for Extracellular Vesicle (EVs) exosome isolation. BioFluidica created LiquidScan to affinity capture and thereby enrich the concentration of biomarkers in liquid biopsy samples. These biomarkers include rare cells like circulating tumor cells (CTCs) and fetal cells (trophoblasts) and, importantly, Extracellular Vesicles (EVs; exosomes). EVs (exosomes) are ideally suited to be developed for liquid biopsy diagnostic analysis for early diagnosis, molecular profiling, disease surveillance, and treatment response monitoring. Numerous studies describe the functional significance of exosomes in a wide variety of cancers, for example. To move research studies into the clinic, however, requires a reproducible accurate, and automated methodology and one that can isolate specific exosome subtypes.
*LiquidScan is the unique solution to isolate exosome subtypes for biomarker research and diagnostics development. BioFluidica exosome experts have experience capturing EVs with antibodies against pan-EV markers (CD9, CD63, CD81) and cancer-specific markers (EPCAM, FAPalpha, CD24, PD-L1).